MedTrace Logo

Gestational Diabetes

NCT04270578 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2022-08-22

No results posted yet for this study

Summary

Due to a changed lifestyle with less physical activity, unfavorable diets rich in fat and calories and obesity, the prevalence of diabetes mellitus is increasing worldwide. The diabetes epidemic is associated with significant personal and socio-economic consequences. Despite attempts to prevent the complications of diabetes, this disease is still the leading cause of blindness, chronic renal insufficiency and non-traumatic amputation. It is important to detect early on an increase in blood sugar and treat it accordingly to reduce costs and to minimize the personal suffering of those affected. As the number of patients with type 2 diabetes mellitus continues to rise, the number of young women with gestational diabetes mellitus (GDM) also increases. This is a disorder og glucose metabolism, which occurs for the first time in pregnancy. The causes for this are manifold. Among other causes, the increasing age of the mothers and weight gain during pregnancy are risk factors for gestational diabetes. Although it has been recommended that women with gestational diabetes should be re-examined after the birth of their child, many women have not. The study is a follow-up study to clarify whether insulin secretion disorder in women with and after GDM is a risk factor for the occurrence of type 2 diabetes mellitus.

Conditions

  • Gestational Diabetes

Sponsors & Collaborators

  • Deutsches Diabeteszentrum (DDZ), Leibniz-Institut Düsseldorf

    collaborator UNKNOWN

  • Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus, TU Dresden

    collaborator UNKNOWN

  • Klinik für Diabetologie an der Medizinischen Klinik - Innenstadt, LMU München

    collaborator UNKNOWN

  • Universitätsklinik Heidelberg, Abteilung Innere Medizin I, Schwerpunkt Endokrinologie und Stoffwechsel

    collaborator UNKNOWN

  • Universitätsklinikum Leipzig, IFB Adipositas Erkrankungen

    collaborator UNKNOWN

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Andreas Fritsche, MD · University Hospital Tuebingen

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-23
Primary Completion
2027-05-01
Completion
2028-05-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04270578 on ClinicalTrials.gov